NSTGQ vs. FRTX, CELZ, PALI, TCON, TTNP, FNCH, KRBP, ALBT, SRNE, and ELOX
Should you be buying NanoString Technologies stock or one of its competitors? The main competitors of NanoString Technologies include Fresh Tracks Therapeutics (FRTX), Creative Medical Technology (CELZ), Palisade Bio (PALI), TRACON Pharmaceuticals (TCON), Titan Pharmaceuticals (TTNP), Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), Avalon GloboCare (ALBT), Sorrento Therapeutics (SRNE), and Eloxx Pharmaceuticals (ELOX). These companies are all part of the "biological products, except diagnostic" industry.
NanoString Technologies (NASDAQ:NSTGQ) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
NanoString Technologies has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.
NanoString Technologies and Fresh Tracks Therapeutics both received 0 outperform votes by MarketBeat users.
In the previous week, NanoString Technologies' average media sentiment score of 0.00 equaled Fresh Tracks Therapeutics'average media sentiment score.
76.8% of NanoString Technologies shares are owned by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. 3.1% of NanoString Technologies shares are owned by company insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Fresh Tracks Therapeutics has lower revenue, but higher earnings than NanoString Technologies. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than NanoString Technologies, indicating that it is currently the more affordable of the two stocks.
Fresh Tracks Therapeutics has a net margin of -91.29% compared to NanoString Technologies' net margin of -102.44%. NanoString Technologies' return on equity of 0.00% beat Fresh Tracks Therapeutics' return on equity.
Summary
Fresh Tracks Therapeutics beats NanoString Technologies on 6 of the 11 factors compared between the two stocks.
Get NanoString Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSTGQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NSTGQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NSTGQ vs. The Competition
NanoString Technologies Competitors List
Related Companies and Tools
